Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 14/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | CCR5 | P51681 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1945961 | 0.93 | CCR2 (0.72) | CCR2KCNH2MEN1NPC1RAB9A | |
| SCHEMBL1945500 | 0.84 | CCR2 (0.61) | CCR2KCNH2MEN1NPC1RAB9A | |
| SCHEMBL1944686 | 0.84 | CYP3A4 (0.71) | CCR2KCNH2MEN1NPC1RAB9A | |
| SCHEMBL10253833 | 0.83 | MEN1 (0.71) | CCR2KCNH2MEN1NPC1RAB9A | |
| SCHEMBL1943530 | 0.83 | CCR2 (0.70) | CCR2KCNH2MEN1NPC1RAB9A | |
| SCHEMBL12538372 | 0.83 | CCR2 (0.70) | CCR2KCNH2MEN1NPC1RAB9A | |
| SCHEMBL1943335 | 0.81 | CCR2 (0.73) | CCR2KCNH2MEN1NPC1RAB9A | |
| SCHEMBL1943449 | 0.81 | CCR2 (0.72) | CCR2KCNH2CYP3A4CYP2D6 | |
| SCHEMBL27979643 | 0.81 | MEN1 (0.84) | CCR2KCNH2MEN1NPC1RAB9A | |
| SCHEMBL1942883 | 0.80 | CCR2 (0.65) | CCR2KCNH2MEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710224-B2 | Heterocyclic compounds as CCR2B antagonists | ASTRAZENECA AB (SE) | 2014-04-29 | — | — | US | disclosed |
| US-20140038978-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | ASTRAZENECA AB (SE) | 2014-02-06 | — | — | US | disclosed |
| US-20120264762-A1 | Heterocyclic Compounds as CCR2 Antagonists | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | US | disclosed |
| US-20110136820-A1 | Heterocyclic Compounds as CCR2 Antagonists | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| US-7906645-B2 | Heterocyclic compounds as ccr2b antagonists | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| US-20090099156-A1 | Heterocyclic Compounds as Ccr2b antagonists | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264762-A1 | Heterocyclic Compounds as CCR2 Antagonists | CCR2, CCR3, CXCR2 | CCR2 1/4885KCNH2 2034/4885MEN1 4557/4885 |
| US-20110136820-A1 | Heterocyclic Compounds as CCR2 Antagonists | CCR2, CCR3, CXCR2 | CCR2 1/4885KCNH2 2034/4885MEN1 4557/4885 |
| US-20140038978-A1 | HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS | CCR2, CCR3, CXCR2 | CCR2 1/4885KCNH2 2490/4885MEN1 4671/4885 |
| US-20090099156-A1 | Heterocyclic Compounds as Ccr2b antagonists | CCR2, CCR3, CXCR2 | CCR2 1/4885KCNH2 2418/4885MEN1 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.